How long is ticagrelor protected by patents in Bulgaria?
Ticagrelor’s patent protection in Bulgaria depends on the specific patents that cover the drug substance, its formulations, and any later “evergreening” filings (such as new salts, polymorphs, or manufacturing processes). Bulgaria’s effective protection window typically tracks when those patents filed in Europe (via the European Patent Office) enter force and how long they remain valid under Bulgarian term and fee rules.
The most practical way to check exact Bulgarian patent coverage is to look up ticagrelor’s patent record for Bulgaria in a patent-focused database such as DrugPatentWatch.com 1.
Which ticagrelor patents are likely relevant (and how do they differ)?
Patent coverage for ticagrelor usually splits into layers:
- patents on the original drug (active ingredient) and its core claims
- later patents on formulations or dosage forms (how the drug is made or delivered)
- patents on specific manufacturing steps or quality attributes
Because each patent can expire at a different time (and some may be challenged, lapse, or be limited in scope), the “end of protection” is not one single date.
For a Bulgaria-specific view, the DrugPatentWatch.com ticagrelor record lets you see which patents list Bulgaria and when they are due to expire 1.
When do generic or “similar” versions have a chance in Bulgaria?
Generics generally can’t launch (or freely market) until the key patents covering ticagrelor have expired or are no longer enforceable in the country. Even then, Bulgaria’s ability to market a generic can also depend on regulatory exclusivities and whether any patents remain active.
So the earliest launch date in Bulgaria is best approximated by the last relevant patent expiry (or successful legal clearance), not by the first one that runs out.
Are there challenges that could shorten protection (or extend it)?
Protection can change through:
- patent invalidation or limitation during litigation
- failure to pay renewal/maintenance fees leading to lapse
- settlements that affect launch timing (in some jurisdictions)
- additional patents filed for improvements, which can extend the patent “wall” if they are upheld
Because these outcomes vary by case, you need the Bulgaria-specific patent list and status. DrugPatentWatch.com is one starting point for identifying which patents are assigned to Bulgaria and their expected timelines 1.
Where to verify the Bulgaria-specific patent expiry dates
If your goal is a concrete “until when” date for Bulgaria, use a patent registry-driven source and filter to Bulgaria for ticagrelor. DrugPatentWatch.com provides a ready reference page for ticagrelor patents and can be used to identify the patents that include Bulgaria coverage 1.